Search
Tafasitamab
go.drugbank.com/drugs/DB15044ApprovedInvestigational[L15302] It is produced using recombinant DNA technology in Chinese hamster ovary cells, and contains an IgG1/2 hybrid Fc-domain which has been modified with 2 amino acid substitutions to enhance its cytotoxicity … [L15292,A191829] The CD19 surface protein is highly expressed on the surface of B-cells, where it appears to play a role in enhancing B-cell receptor signaling.
Concizumab
go.drugbank.com/drugs/DB12820ApprovedInvestigationalConcizumab therefore provides an important treatment option for patients who have developed inhibitors to standard clotting factor replacement therapy. … [L51998,A264878] This novel mechanism of action is effective even in the presence of inhibitors towards factors VIII or IX, as it essentially skips the intrinsic pathway in which factors VIII and IX participate
Adenosine phosphate
go.drugbank.com/drugs/DB00131ApprovedInvestigationalNutraceuticalWithdrawnAdenosine phosphate, or adenylic acid, is an adenine nucleotide containing one phosphate group esterified to the sugar moiety in the 2'-, 3'-, or 5'-position. … Adenosine phosphate was withdrawn by the FDA since it was considered neither safe nor effective for its intended uses as a vasodilator and an anti-inflammatory.[L43937]
Econazole
go.drugbank.com/drugs/DB01127ApprovedIt is used topically in dermatomycoses also orally and parenterally.
Upinitatug rilsodotin
go.drugbank.com/drugs/DB19104InvestigationalUpinitatug rilsodotin is under investigation in clinical trial NCT05329545 (Upifitamab Rilsodotin Maintenance in Platinum-sensitive Recurrent Ovarian Cancer (UP-NEXT)).
Lefamulin
go.drugbank.com/drugs/DB12825Approved[A183206] Lefamulin is available in intravenous and oral preparations and was granted FDA approval in August 2019. … A pleuromotilin is a more recently developed type of antibiotic that is derived from the fungus, Pleurotus mutilus.
Atrasentan
go.drugbank.com/drugs/DB06199ApprovedInvestigationalAtrasentan is a novel, selective endothelin A receptor antagonist (SERA). … [L52855] In April 2025, atrasentan was granted accelerated approval by the FDA for the reduction of proteinuria in patients with primary IgA nephropathy, becoming the first endothelin A receptor antagonist
Categories: Endothelin Receptor Antagonists, Endothelin A Receptor AntagonistsVotucalis
go.drugbank.com/drugs/DB05032InvestigationalrEV131 is in development for allergic rhinitis, asthma and several inflammatory eye diseases. It is a topically delivered small protein that acts as an anti-inflammatory agent.
Clomifene
go.drugbank.com/drugs/DB00882ApprovedInvestigationalA triphenyl ethylene stilbene derivative which is an estrogen agonist or antagonist depending on the target tissue.
Categories: Estrogen Receptor Modulators, Selective Estrogen Receptor ModulatorsBeta-ketoacyl-[acyl-carrier-protein] synthase III
go.drugbank.com/bio_entities/BE0000558TargetEscherichia coli (strain K12)Catalyzes the condensation reaction of fatty acid synthesis by the addition to an acyl acceptor of two carbons from malonyl-ACP. Catalyzes the first condensation reaction which initiates fatty acid synthesis and may therefore play a role...
Synonyms: KAS III